The Inside Mystery of Jejunal Gastrointestinal Stromal Tumor: A Rare Case Report and Review of the Literature

Gastrointestinal stromal tumors (GISTs) are malignant and rare form of soft tissue sarcoma of the digestive tract. The incidence of gastrointestinal stromal tumors is very low Kramer et al. 2005 Jejunal GISTs are extremely rare. Here we present a rare case of jejunal GIST with unusually large size at presentation. The patient presented with severe abdomen pain, exophytic growth, and dimorphic anemia. Surgical resection of the tumor was carried out, and operative findings revealed a 15 × 10 cm growth, arising from serosal surface of jejunum, at the antimesenteric surface. Diagnosis in this case was made by subjecting the resected specimen to immunohistochemical analysis. In view of large size of the resected tumor, and high-risk histopathological features, imatinib mesylate 400 mg once daily was given as adjuvant chemotherapy. Patient is asymptomatic without any evidence of tumor recurrence after six months of postoperative followup. Imatinib as such is recommended in metastatic, residual or recurrent cases of GISTs or which are surgically not removable; however, recent recommendations suggests the use of imatinib mesylate after radical surgery in high-risk cases, because it has shown a significant decrease in the recurrence rate, and the Food and Drug Administration (FDA) has also approved the use of imatinib as adjuvant therapy after complete resection of localized, primary GIST

Prucalopride: novel drug for chronic idiopathic constipation

Chronic Idiopathic Constipation (CIC), defined as constipation in which the underlying cause is unknown, is a common medical illness with a profound negative impact on health-related quality of life and increased propensity for life threatening complications. Current treatment for CIC includes lifestyle modifications, over-the-counter medications, and prescription medications. Presently, the only approved, prescription products for CIC in the US are prosecretory agents. However, the current knowledge that serotonin plays an important role in colonic motility has opened new horizons in the treatment of CIC promoting use of prokinetic agents with a different mechanism of action. Prucalopride is a highly selective 5-hydroxytryptamine type 4 (5-HT4) receptor agonist that enhances propulsive motor patterns in the large intestine due to a high affinity for 5-HT4 receptors in gastrointestinal (GI) tissues.  The onset of action of Prucalopride is fast, shows rapid absorption, oral bioavailability of 93% and linear pharmacokinetics. Most common adverse reactions seen are headache, nausea, diarrhea, and abdominal pain. Clinical trials for Prucalopride have been positive, and results suggest that the drug may be a new safe and effective option for CIC treatment, especially for patient’s refractory to prosecretory agents. As a prescription drug for the management of constipation and given the virtual demise of other prokinetic agents for this indication, prucalopride competes primarily with another class of agents: those that stimulate secretion. With Shire Pharmaceuticals having already received US FDA approval in Dec 2018, Prucalopride may soon be a new addition to the mounting armoury of drugs against CIC

Mechanical, antibacterial and bond strength properties of nano-titanium-enriched glass ionomer cement

The use of nanoparticles (NPs) has become a significant area of research in Dentistry. Objective The aim of this study was to investigate the physical, antibacterial activity and bond strength properties of conventional base, core build and restorative of glass ionomer cement (GIC) compared to GIC supplemented with titanium dioxide (TiO2) nanopowder at 3% and 5% (w/w). Material and Methods Vickers microhardness was estimated with diamond indenter. Compressive and flexural strengths were analyzed in a universal testing machine. Specimens were bonded to enamel and dentine, and tested for shear bond strength in a universal testing machine. Specimens were incubated with S. mutans suspension for evaluating antibacterial activity. Surface analysis of restorative conventional and modified GIC was performed with SEM and EDS. The analyses were carried out with Kolmogorov-Smirnov, ANOVA (post-hoc), Tukey test, Kruskal-Wallis, and Mann Whitney. Results Conventional GIC and GIC modified with TiO2 nanopowder for the base/liner cement and core build showed no differences for mechanical, antibacterial, and shear bond properties (p>0.05). In contrast, the supplementation of TiO2 NPs to restorative GIC significantly improved Vickers microhardness (p<0.05), flexural and compressive strength (p<0.05), and antibacterial activity (p<0.001), without interfering with adhesion to enamel and dentin. Conclusion GIC supplemented with TiO2 NPs (FX-II) is a promising material for restoration because of its potential antibacterial activity and durable restoration to withstand the mastication force

Highlights of 2nd Taiwan International Congress of Parkinson's Disease and Movement Disorders, Taipei, Taiwan (March 28-29, 2015): Parkinson's Disease and Movement Disorder- an Update

2nd Taiwan International Congress of Parkinson's disease and Movement disorders was held at Taipei, Taiwan from 28-29thMarch 2015. Present report highlights various cellular and molecular aspects on the Parkinson's disease and relatedmovement disorders. In brief, report provides a comprehensive overview to understand the etiopathogenesis of PD andrelated movement disorders. Neuroscientists and young researchers from all around the world presented their recentadvancement with a wide range of scopes of neurodegeneration research, including new genes, molecular pathways, animalmodels, and potential therapeutics. Present conference report is mix blend of various deliberations consists of plenarylectures, symposia and oral and poster presentations

Additional file 2: Figure S2. of Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients

Quantification using the inbuilt Leica software (a). The white arrowhead represents the fluorescent area selected for the intensity measurement using poly-line profile for each cell, referred to as the region of interest (ROI). Twenty cells per image were considered for each of the 10 images taken per cover slip. b The report generated by the software. The mean intensity was taken for each ROI and further analyzed. (TIF 7393 KB

Additional file 1: Figure S1. of Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients

Representative phase contrast (a, c–e) and confocal images of the enriched astroglial cultures (b, f–h). The reactive astrocytes display a process bearing morphology (e, h) as compared to the flat morphology adopted by the non-reactive astrocytes (c, f). The intermediate stages show a semi-reactive morphology with a transformation from flat to process bearing one (d, g). The cultures were found to be free of microglia as seen by the presence of GFAP immunoreactivity (red, j) and absence of Iba1 (green, i). In a similar manner, the cultures were found to be ChAT negative (green, l). The cultures were >99 % pure. Scale bars are indicated. (TIF 14438 kb

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research

Experimental models that faithfully mimic the developmental pathology of sporadic Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic approaches in sAD treatment. Widely used transgenic mice AD models have provided valuable insights into the molecular mechanisms underlying the memory decline but, due to the particular β-amyloid-related gene manipulation, they resemble the familial but not the sporadic AD form, and are, therefore, inappropriate for this purpose. In line with the recent findings of sAD being recognised as an insulin resistant brains state (IRBS), a new, non-transgenic, animal model has been proposed as a representative model of sAD, developed by intracerebroventricular application of the betacytotoxic drug streptozotocin (STZ-icv). The STZ-icv-treated animals (mostly rats and mice) develop IRBS associated with memory impairment and progressive cholinergic deficits, glucose hypometabolism, oxidative stress and neurodegeneration that share many features in common with sAD in humans. The therapeutic strategies (acetylcholinesterase inhibitors, antioxidants and many other drugs) that have been tested until now on the STZ-icv animal model have been reviewed and the comparability of the drugs' efficacy in this non-transgenic sAD model and the results from clinical trials on sAD patients, evaluated